ReviewEndocrinology2008
Insulin-like growth factors in the peripheral nervous system.
Review in Endocrinology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 70 citations in OpenAlex.
- Effect of curcumin andFrontiers in neuroscience · 2026Article
- Functional Equivalence of Insulin and IGF-1 in the In Vitro Culture of Chicken Primordial Germ Cells.Genes · 2025Article
- Pharmacologically targeting Schwann cells to improve regeneration following nerve damage.Frontiers in cell and developmental biology · 2025Review
- Article
- BDNF and Krox20 as Indicators of Platelet-rich Plasma-Induced Nerve Regeneration in a Neuropathic Orofacial Pain Model.European journal of dentistry · 2024Article
- Stem cell therapy combined with controlled release of growth factors for the treatment of sphincter dysfunction.Cell & bioscience · 2023Review
- The Role of c-Jun and Autocrine Signaling Loops in the Control of Repair Schwann Cells and Regeneration.Frontiers in cellular neuroscience · 2021Review
- Intrathecal IGF2 siRNA injection provides long-lasting anti-allodynic effect in a spared nerve injury rat model of neuropathic pain.PloS one · 2021Article
- Decellularized skeletal muscles display neurotrophic effects in three-dimensional organotypic cultures.Stem cells translational medicine · 2020Article
- Genome-wide profiling of DNA methylation and gene expression identifies candidate genes for human diabetic neuropathy.Clinical epigenetics · 2020Article
- Disrupting insulin signaling in Schwann cells impairs myelination and induces a sensory neuropathy.Glia · 2020Article
- Biomimetic Approaches for Separated Regeneration of Sensory and Motor Fibers in Amputee People: Necessary Conditions for Functional Integration of Sensory-Motor Prostheses With the Peripheral Nerves.Frontiers in bioengineering and biotechnology · 2020Article
- Nerve, Muscle, and Synaptogenesis.Cells · 2019Review
- KIF1Bβ mutations detected in hereditary neuropathy impair IGF1R transport and axon growth.The Journal of cell biology · 2018Article
- Integrins promote axonal regeneration after injury of the nervous system.Biological reviews of the Cambridge Philosophical Society · 2018Review
- Systemic IGF-1 gene delivery by rAAV9 improves spontaneous autoimmune peripheral polyneuropathy (SAPP).Scientific reports · 2018Article
- IRS proteins and diabetic complications.Diabetologia · 2016Review
- IGF1 potentiates BMP9-induced osteogenic differentiation in mesenchymal stem cells through the enhancement of BMP/Smad signaling.BMB reports · 2016Article
- Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin.Muscle & nerve · 2014Article
- Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
IGF-I and -II are potent neuronal mitogens and survival factors. The actions of IGF-I and -II are mediated via the type I IGF receptor (IGF-IR) and IGF binding proteins regulate the bioavailability of the IGFs. Cell viability correlates with IGF-IR expression and intact IGF-I/IGF-IR signaling pathways, including activation of MAPK/phosphatidylinositol-3 kinase. The expression of IGF-I and -II, IGF-IR, and IGF binding proteins are developmentally regulated in the central and peripheral nervous system. IGF-I therapy demonstrates mixed therapeutic results in the treatment of peripheral nerve injury, neuropathy, and motor neuron diseases such as amyotrophic lateral sclerosis. In this review we discuss the role of IGFs during peripheral nervous system development and the IGF signaling system as the potential therapeutic target for the treatment of nerve injury and motor neuron diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.